Are there therapeutic strategies targeting mTORC1?
Yes, there are several therapeutic strategies aimed at modulating mTORC1 activity. Rapamycin and its analogs (rapalogs) are well-known inhibitors of mTORC1 and have been used in clinical settings to treat certain cancers and prevent organ transplant rejection. Additionally, ongoing research is exploring novel mTOR inhibitors and combination therapies to more effectively target mTORC1-related pathologies while minimizing side effects.
